Remie Bastiaansen

Remie Bastiaansen is a Senior Investment Manager at BOM Brabant Ventures, the investment unit of De Brabantse Ontwikkelings Maatschappij (BOM), the regional development agency for the Dutch province of Noord-Brabant. BOM invests public capital to strengthen the Brabant innovation economy, and Bastiaansen evaluates and leads early-stage venture deals across the agency's focus sectors — frequently in capital-intensive hardware, medical-device, and deep-tech companies that are characteristic of the Brainport Eindhoven ecosystem.

His academic background is in innovation and entrepreneurship: he pursued a Master of Science at Lund University's School of Economics and Management in Sweden, a focus that aligns closely with his current work backing technology founders. In aggregator profiles he is described as concentrating on venture capital investments that deliver meaningful economic and social impact for the Brabant region.

Within BOM he works alongside a sizable investment team that includes colleagues such as Bart Mul, Bart van den Heuvel, Brigit van Dijk – van de Reijt, Daan van Lange, and Ernst Coolen. Because BOM is an "evergreen," government-backed investor rather than a time-boxed private fund, Bastiaansen can take a longer-horizon, regionally-anchored approach than a typical seed VC. Note that the original stub describing him as an "Investment Analyst" at an "Angel Investors" firm is inaccurate — he is a senior manager at an institutional regional VC.

• Stage & size: Backs companies from pre-seed through Series A, writing checks roughly in the $100K–$5.0M range, with a typical sweet spot near $1.5M.
• Sectors: Hardware and "key technologies," health tech / medical devices, SaaS, industrial tech, sustainable food, climate-neutral energy, AR/VR, and (more recently) game development.
• Regional mandate: As a BOM manager, a central "yes" criterion is impact on the Brabant economy — companies based in or expanding into Noord-Brabant, contributing jobs and innovation locally. On the Twirlbound deal he framed the rationale explicitly: *"The investment in Twirlbound directly contributes to positioning Breda as an international game hub."*
• Cost-effective, evidence-backed innovation (health tech): On Post-ICU he noted the appeal of a clinically endorsed product that is cheap to deploy — *"When we understood that an ICU diary was being advised by many professional critical care associations, we saw the potential of the digital equivalent,"* highlighting it as a cost-effective intervention that also improves patient satisfaction.
• Category-defining deep tech: On ANTENNEX he emphasized backing companies at the leading edge of a technology shift — *"The transition to having more antennas integrated in devices will revolutionise various industries... Antennex is at the forefront of this transition, providing essential testing solutions."*